Difference between revisions of "Factor V"

Jump to: navigation, search
(Role in disease)
 
(4 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{PBB_Controls
+
{{About|the blood coagulation protein|the software company|Factor 5}}
| update_page = yes
 
| require_manual_inspection = no
 
| update_protein_box = yes
 
| update_summary = no
 
| update_citations = yes
 
}}
 
{{GNF_Protein_box
 
| image = PBB_Protein_F5_image.jpg
 
| image_source = [[Protein_Data_Bank|PDB]] rendering based on 1czs.
 
| Name = Coagulation factor V (proaccelerin, labile factor)
 
| HGNCid = 3542
 
| Symbol = F5
 
| AltSymbols =; FVL; PCCF; factor V
 
| OMIM = 227400
 
| ECnumber = 
 
| Homologene = 104
 
| MGIid = 88382
 
| GeneAtlas_image1 = PBB_GE_F5_204714_s_at_tn.png
 
| GeneAtlas_image2 = PBB_GE_F5_204713_s_at_tn.png
 
| Function = {{GNF_GO|id=GO:0005507 |text = copper ion binding}} {{GNF_GO|id=GO:0005509 |text = calcium ion binding}} {{GNF_GO|id=GO:0016491 |text = oxidoreductase activity}}
 
| Component = {{GNF_GO|id=GO:0005576 |text = extracellular region}}
 
| Process = {{GNF_GO|id=GO:0007155 |text = cell adhesion}} {{GNF_GO|id=GO:0007596 |text = blood coagulation}}
 
| Orthologs = {{GNF_Ortholog_box
 
    | Hs_EntrezGene = 2153
 
    | Hs_Ensembl = ENSG00000198734
 
    | Hs_RefseqProtein = NP_000121
 
    | Hs_RefseqmRNA = NM_000130
 
    | Hs_GenLoc_db = 
 
    | Hs_GenLoc_chr = 1
 
    | Hs_GenLoc_start = 167750028
 
    | Hs_GenLoc_end = 167822450
 
    | Hs_Uniprot = P12259
 
    | Mm_EntrezGene = 14067
 
    | Mm_Ensembl = ENSMUSG00000026579
 
    | Mm_RefseqmRNA = NM_007976
 
    | Mm_RefseqProtein = NP_032002
 
    | Mm_GenLoc_db = 
 
    | Mm_GenLoc_chr = 1
 
    | Mm_GenLoc_start = 165988633
 
    | Mm_GenLoc_end = 166056227
 
    | Mm_Uniprot = 
 
  }}
 
}}
 
{{SI}}
 
{{CMG}}
 
  
{{EH}}
+
{{Infobox_gene}}
 +
'''Factor V''' (pronounced '''factor five''') is a [[protein]] of the [[coagulation]] system, rarely referred to as '''proaccelerin''' or '''labile factor'''. In contrast to most other coagulation factors, it is not enzymatically active but functions as a [[cofactor (biochemistry)|cofactor]]. Deficiency leads to predisposition for [[hemorrhage]], while some mutations (most notably [[factor V Leiden]]) predispose for [[thrombosis]].
  
'''Factor V''' is a [[protein]] of the [[coagulation]] system, rarely referred to as '''proaccelerin''' or '''labile factor'''. In contrast to most other coagulation factors, it is not enzymatically active but functions as a [[cofactor]]. Deficiency leads to predisposition for [[hemorrhage]], while some mutations (most notably [[factor V Leiden]]) predispose for [[thrombosis]].
+
==Genetics==
 +
The [[gene]] for factor V is located on the [[first chromosome]] (1q23). It is genomically related to the family of [[multicopper oxidase]]s, and is homologous to coagulation [[factor VIII]]. The gene spans 70 kb, consists of 25 exons, and the resulting protein has a relative molecular mass of approximately 330kDa.
  
==Genetics==
+
==Structure==
The [[gene]] for factor V is located on the first [[chromosome]] (1q23). It is genomically related to the family of multicopper oxidases, and is homologous to coagulation factor VIII. The gene spans 70 kb, consists of 25 exons, and the resulting protein has a relative molecular mass of approximately 330000.
+
Factor V protein consists of six domains: A1-A2-B-A3-C1-C2.
 +
 
 +
The A domains are [[homology (biology)|homologous]] to the A domains of the copper-binding protein [[ceruloplasmin]], and form a triangular as in that protein. A copper ion is bound in the A1-A3 interface, and A3 interacts with the plasma.<ref>{{cite journal | vauthors = Villoutreix BO, Dahlbäck B | title = Structural investigation of the A domains of human blood coagulation factor V by molecular modeling | journal = Protein Science | volume = 7 | issue = 6 | pages = 1317–25 | date = June 1998 | pmid = 9655335 | doi = 10.1002/pro.5560070607 | pmc=2144041}}</ref>
 +
 
 +
The C domains belong to the  [[phospholipid]]-binding [[discoidin domain]] family, and the C2 domain mediate membrane binding. The B domain [[C-terminus]] acts as a [[cofactor (biochemistry)|cofactor]] for the [[anticoagulant]] [[protein C]] activation by [[protein S]].<ref name = "Thorelli1998">{{cite journal | vauthors = Thorelli E, Kaufman RJ, Dahlbäck B | title = The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V | journal = The Journal of Biological Chemistry | volume = 273 | issue = 26 | pages = 16140–5 | date = June 1998 | pmid = 9632668 | doi=10.1074/jbc.273.26.16140}}</ref>
 +
<ref>{{cite journal | vauthors = Macedo-Ribeiro S, Bode W, Huber R, Quinn-Allen MA, Kim SW, Ortel TL, Bourenkov GP, Bartunik HD, Stubbs MT, Kane WH, Fuentes-Prior P | title = Crystal structures of the membrane-binding C2 domain of human coagulation factor V | journal = Nature | volume = 402 | issue = 6760 | pages = 434–9 | date = November 1999 | pmid = 10586886 | doi = 10.1038/46594 }}</ref>
 +
 
 +
Activation of factor V to factor Va is done by cleavage and release of the B domain, after which the protein no longer assists in activating protein C. The protein is now divided to a heavy chain, consisting of the A1-A2 domains, and a light chain, consisting of the A3-C1-C2 domains. Both form non-covalently a complex in a calcium-dependent manner. This complex is the pro-coagulant factor Va.<ref name="Thorelli1998" />
  
 
==Physiology==
 
==Physiology==
Factor V circulates in plasma as a single-chain molecule with a plasma half-life of about 12 hours. Half-lives up to 36 hours have been reported, though.
+
Factor V synthesis occurs in the liver, principally. The molecule circulates in plasma as a single-chain molecule with a plasma half-life of 12–36 hours.<ref name="HuangKoerper2008">{{cite journal | vauthors = Huang JN, Koerper MA | title = Factor V deficiency: a concise review | journal = Haemophilia | volume = 14 | issue = 6 | pages = 1164–9 | date = November 2008 | pmid = 19141156 | doi = 10.1111/j.1365-2516.2008.01785.x }}</ref>
  
Factor V is able to bind to activated [[platelet]]s and is activated by [[thrombin]]. On activation, factor V is spliced in two chains (heavy and light chain with molecular masses of 110000 and 73000, respectively) which are nonconvalently bound to each other by [[calcium in biology|calcium]]. Factor V is active as a cofactor of the thrombinase complex. The activated [[factor X]] (FXa) enzyme requires [[calcium in biology|Ca<sup>++</sup>]] and activated factor V to convert prothrombin to [[thrombin]] on the cell surface membrane. This is considered part of the common pathway in the coagulation cascade.
+
Factor V is able to bind to activated [[platelet]]s and is activated by [[thrombin]]. On activation, factor V is spliced in two chains (heavy and light chain with molecular masses of 110000 and 73000, respectively) which are noncovalently bound to each other by [[calcium in biology|calcium]]. The thereby activated factor V (now called FVa) is a cofactor of the [[prothrombinase]] complex: The activated [[factor X]] (FXa) enzyme requires calcium and activated factor V to convert prothrombin to [[thrombin]] on the cell surface membrane.
  
 
Factor Va is degraded by [[protein C|activated protein C]], one of the principal physiological inhibitors of coagulation. In the presence of [[thrombomodulin]], thrombin acts to decrease clotting by activating Protein C; therefore, the concentration and action of protein C are  important determinants in the negative feedback loop through which thrombin limits its own activation.
 
Factor Va is degraded by [[protein C|activated protein C]], one of the principal physiological inhibitors of coagulation. In the presence of [[thrombomodulin]], thrombin acts to decrease clotting by activating Protein C; therefore, the concentration and action of protein C are  important determinants in the negative feedback loop through which thrombin limits its own activation.
Line 66: Line 30:
  
 
==History==
 
==History==
Until the discovery of factor V, coagulation was regarded as a product of four factors: [[calcium]] (IV) and thrombokinase (III) together acting on [[prothrombin]] (II) to produce [[fibrinogen]] (I); this model had been outlined by [[Paul Morawitz]] in 1905.<ref name=Stormorken>{{cite journal |author=Stormorken H |title=The discovery of factor V: a tricky clotting factor |journal=J. Thromb. Haemost. |volume=1 |issue=2 |pages=206-13 |year=2003 |pmid=12871488 |doi=}}</ref>
+
Until the discovery of factor V, coagulation was regarded as a product of four factors: [[calcium]] (IV) and thrombokinase (III) together acting on [[prothrombin]] (II) to produce [[fibrinogen]] (I); this model had been outlined by [[Paul Morawitz]] in 1905.<ref name=Stormorken>{{cite journal | vauthors = Stormorken H | title = The discovery of factor V: a tricky clotting factor | journal = Journal of Thrombosis and Haemostasis | volume = 1 | issue = 2 | pages = 206–13 | date = February 2003 | pmid = 12871488 | doi = 10.1046/j.1538-7836.2003.00043.x | authorlink = Helge Stormorken }}</ref>
  
The suggestion that an additional factor might exist was made by Dr Paul Owren (1905-1990), a Norwegian physician, during his investigations into the bleeding tendency of a lady called Mary (1914-2002). She had suffered from [[epistaxis|nosebleeds]] and [[menorrhagia]] (excessive menstrual blood loss) for most her life, and was found to have a prolonged [[prothrombin time]], suggesting either [[vitamin K]] deficiency or [[chronic liver disease]] leading to prothrombin deficiency. However, neither were the case, and Owren demonstrated this by correcting the abnormality with plasma from which prothrombin had been removed. Using Mary's serum as index, he found that the "missing" factor, which he labeled V (I-IV having been used in Morawitz' model), had particular characteristics. Most investigations were performed during the Second World War, and while Owren published his results in Norway in 1944, he could not publish them internationally until the war was over. They appeared finally in ''[[The Lancet]]'' in 1947.<ref>{{cite journal |last=Owren |first=PA |year=1947 |title=Parahaemophilia. Haemorrhagic diathesis due to absence of a previously unknown clotting factor. |journal=Lancet |volume=1 |pages=446-51}}</ref><ref name=Stormorken/>
+
The suggestion that an additional factor might exist was made by Dr Paul Owren (1905–1990), a [[Norway|Norwegian]] physician, during his investigations into the bleeding tendency of a lady called Mary (1914–2002). She had suffered from [[epistaxis|nosebleeds]] and [[menorrhagia]] (excessive menstrual blood loss) for most her life, and was found to have a prolonged [[prothrombin time]], suggesting either [[vitamin K]] deficiency or [[chronic liver disease]] leading to prothrombin deficiency. However, neither were the case, and Owren demonstrated this by correcting the abnormality with plasma from which prothrombin had been removed. Using Mary's serum as index, he found that the "missing" factor, which he labeled V (I-IV having been used in Morawitz' model), had particular characteristics. Most investigations were performed during the [[World War II|Second World War]], and while Owren published his results in Norway in 1944, he could not publish them internationally until the war was over. They appeared finally in ''[[The Lancet]]'' in 1947.<ref name=Stormorken/><ref>{{cite journal | vauthors = Owren PA | title = Parahaemophilia; haemorrhagic diathesis due to absence of a previously unknown clotting factor | journal = Lancet | volume = 1 | issue = 6449 | pages = 446–8 | date = April 1947 | pmid = 20293060 | doi = 10.1016/S0140-6736(47)91941-7 }}</ref>
  
 
The possibility of an extra coagulation factor was initially resisted on methodological grounds by Drs Armand Quick and Walter Seegers, both world authorities in coagulation. Confirmatory studies from other groups led to their final approval several years later.<ref name=Stormorken/>
 
The possibility of an extra coagulation factor was initially resisted on methodological grounds by Drs Armand Quick and Walter Seegers, both world authorities in coagulation. Confirmatory studies from other groups led to their final approval several years later.<ref name=Stormorken/>
  
Owner initially felt that factor V (labile factor or proaccelerin) activated another factor, which he named VI. VI was the factor that accelerated the conversion from prothrombin to thrombin. It was later discovered that factor V was "converted" (activated) by thrombin itself, and later still that factor VI was simply the activated form of factor V.<ref name=Stormorken/>
+
Owren initially felt that factor V (labile factor or proaccelerin) activated another factor, which he named VI. VI was the factor that accelerated the conversion from prothrombin to thrombin. It was later discovered that factor V was "converted" (activated) by thrombin itself, and later still that factor VI was simply the activated form of factor V.<ref name=Stormorken/>
 +
 
 +
The complete amino acid sequence of the protein was published in 1987.<ref>{{cite journal | vauthors = Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG | title = Complete cDNA and derived amino acid sequence of human factor V | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 84 | issue = 14 | pages = 4846–50 | date = July 1987 | pmid = 3110773 | pmc = 305202 | doi = 10.1073/pnas.84.14.4846 }}</ref> In 1994 [[factor V Leiden]], resistant to inactivation by [[protein C]], was described; this abnormality is the most common genetic cause for [[thrombosis]].<ref>{{cite journal | vauthors = Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH | title = Mutation in blood coagulation factor V associated with resistance to activated protein C | journal = Nature | volume = 369 | issue = 6475 | pages = 64–7 | date = May 1994 | pmid = 8164741 | doi = 10.1038/369064a0 }}</ref>
  
The complete amino acid sequence of the protein was published in 1987.<ref>{{cite journal |author=Jenny RJ, Pittman DD, Toole JJ, ''et al'' |title=Complete cDNA and derived amino acid sequence of human factor V |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=84 |issue=14 |pages=4846-50 |year=1987 |pmid=3110773 |doi=}}</ref> In 1994 [[factor V Leiden]], resistant to inactivation by [[protein C]], was described; this abnormality is the most common genetic cause for [[thrombosis]].<ref>{{cite journal |author=Bertina RM, Koeleman BP, Koster T, ''et al'' |title=Mutation in blood coagulation factor V associated with resistance to activated protein C |journal=Nature |volume=369 |issue=6475 |pages=64-7 |year=1994 |pmid=8164741 |doi=10.1038/369064a0}}</ref>
+
== Interactions ==
  
==References==
+
Factor V has been shown to [[Protein-protein interaction|interact]] with [[Protein S]].<ref name=pmid10593904>{{cite journal | vauthors = Heeb MJ, Kojima Y, Rosing J, Tans G, Griffin JH | title = C-terminal residues 621-635 of protein S are essential for binding to factor Va | journal = The Journal of Biological Chemistry | volume = 274 | issue = 51 | pages = 36187–92 | date = December 1999 | pmid = 10593904 | doi = 10.1074/jbc.274.51.36187 }}</ref><ref name=pmid8428962>{{cite journal | vauthors = Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH | title = Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C | journal = The Journal of Biological Chemistry | volume = 268 | issue = 4 | pages = 2872–7 | date = February 1993 | pmid = 8428962 }}</ref>
{{reflist}}
 
  
==Further reading==
+
== References ==
{{refbegin | 2}}
+
{{Reflist|33em}}
{{PBB_Further_reading
+
 
| citations =  
+
== Further reading ==
*{{cite journal | author=Hooper WC, De Staercke C |title=The relationship between FV Leiden and pulmonary embolism. |journal=Respir. Res. |volume=3 |issue= |pages= 8 |year= 2006 |pmid= 11806843 |doi= }}
+
{{refbegin|33em}}
*{{cite journal | author=Schrijver I, Houissa-Kastally R, Jones CD, ''et al.'' |title=Novel factor V C2-domain mutation (R2074H) in two families with factor V deficiency and bleeding. |journal=Thromb. Haemost. |volume=87 |issue= 2 |pages= 294-9 |year= 2002 |pmid= 11858490 |doi=  }}
+
* {{cite journal | vauthors = Nicolaes GA, Dahlbäck B | title = Factor V and thrombotic disease: description of a janus-faced protein | journal = Arteriosclerosis, Thrombosis, and Vascular Biology | volume = 22 | issue = 4 | pages = 530–8 | date = April 2002 | pmid = 11950687 | doi = 10.1161/01.ATV.0000012665.51263.B7 }}
*{{cite journal | author=Mann KG, Kalafatis M |title=Factor V: a combination of Dr Jekyll and Mr Hyde. |journal=Blood |volume=101 |issue= 1 |pages= 20-30 |year= 2003 |pmid= 12393635 |doi= 10.1182/blood-2002-01-0290 }}
+
* {{cite journal | vauthors = Segers K, Dahlbäck B, Nicolaes GA | title = Coagulation factor V and thrombophilia: background and mechanisms | journal = Thrombosis and Haemostasis | volume = 98 | issue = 3 | pages = 530–42 | date = September 2007 | pmid = 17849041 | doi = 10.1160/th07-02-0150 }}
*{{cite journal | author=Duga S, Asselta R, Tenchini ML |title=Coagulation factor V. |journal=Int. J. Biochem. Cell Biol. |volume=36 |issue= 8 |pages= 1393-9 |year= 2005 |pmid= 15147718 |doi= 10.1016/j.biocel.2003.08.002 }}
+
* {{cite journal | vauthors = Hooper WC, De Staercke C | title = The relationship between FV Leiden and pulmonary embolism | journal = Respiratory Research | volume = 3 | issue = 1 | pages = 8 | year = 2006 | pmid = 11806843 | pmc = 64819 | doi = 10.1186/rr180 }}
*{{cite journal | author=Andreassi MG, Botto N, Maffei S |title=Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening. |journal=Clin. Chem. Lab. Med. |volume=44 |issue= 5 |pages= 514-21 |year= 2006 |pmid= 16681418 |doi= 10.1515/CCLM.2006.103 }}
+
* {{cite journal | vauthors = Schrijver I, Houissa-Kastally R, Jones CD, Garcia KC, Zehnder JL | title = Novel factor V C2-domain mutation (R2074H) in two families with factor V deficiency and bleeding | journal = Thrombosis and Haemostasis | volume = 87 | issue = 2 | pages = 294–9 | date = February 2002 | pmid = 11858490 | doi =  }}
*{{cite journal | author=Du X |title=Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. |journal=Curr. Opin. Hematol. |volume=14 |issue= 3 |pages= 262-9 |year= 2007 |pmid= 17414217 |doi= 10.1097/MOH.0b013e3280dce51a }}
+
* {{cite journal | vauthors = Mann KG, Kalafatis M | title = Factor V: a combination of Dr Jekyll and Mr Hyde | journal = Blood | volume = 101 | issue = 1 | pages = 20–30 | date = January 2003 | pmid = 12393635 | doi = 10.1182/blood-2002-01-0290 }}
}}
+
* {{cite journal | vauthors = Duga S, Asselta R, Tenchini ML | title = Coagulation factor V | journal = The International Journal of Biochemistry & Cell Biology | volume = 36 | issue = 8 | pages = 1393–9 | date = August 2004 | pmid = 15147718 | doi = 10.1016/j.biocel.2003.08.002 }}
 +
* {{cite journal | vauthors = Andreassi MG, Botto N, Maffei S | title = Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening | journal = Clinical Chemistry and Laboratory Medicine | volume = 44 | issue = 5 | pages = 514–21 | year = 2006 | pmid = 16681418 | doi = 10.1515/CCLM.2006.103 }}
 +
* {{cite journal | vauthors = Du X | title = Signaling and regulation of the platelet glycoprotein Ib-IX-V complex | journal = Current Opinion in Hematology | volume = 14 | issue = 3 | pages = 262–9 | date = May 2007 | pmid = 17414217 | doi = 10.1097/MOH.0b013e3280dce51a }}
 
{{refend}}
 
{{refend}}
  
==External links==
+
== External links ==
 
* [http://macromoleculeinsights.com/coagulationfactorv.php The Coagulation Factor V Protein]
 
* [http://macromoleculeinsights.com/coagulationfactorv.php The Coagulation Factor V Protein]
  
 +
{{PDB Gallery|geneid=2153}}
 
{{Coagulation}}
 
{{Coagulation}}
{{SIB}}
 
  
 
[[Category:Coagulation system]]
 
[[Category:Coagulation system]]
[[Category:Hematology]]
 
 
 
[[de:Proaccelerin]]
 
[[fr:Proaccélérine]]
 
[[pl:Proakceleryna]]
 
[[pt:Factor V]]
 
[[sv:Faktor V]]
 
 
{{WikiDoc Help Menu}}
 
{{WikiDoc Sources}}
 

Latest revision as of 14:00, 12 September 2018

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Factor V (pronounced factor five) is a protein of the coagulation system, rarely referred to as proaccelerin or labile factor. In contrast to most other coagulation factors, it is not enzymatically active but functions as a cofactor. Deficiency leads to predisposition for hemorrhage, while some mutations (most notably factor V Leiden) predispose for thrombosis.

Genetics

The gene for factor V is located on the first chromosome (1q23). It is genomically related to the family of multicopper oxidases, and is homologous to coagulation factor VIII. The gene spans 70 kb, consists of 25 exons, and the resulting protein has a relative molecular mass of approximately 330kDa.

Structure

Factor V protein consists of six domains: A1-A2-B-A3-C1-C2.

The A domains are homologous to the A domains of the copper-binding protein ceruloplasmin, and form a triangular as in that protein. A copper ion is bound in the A1-A3 interface, and A3 interacts with the plasma.[1]

The C domains belong to the phospholipid-binding discoidin domain family, and the C2 domain mediate membrane binding. The B domain C-terminus acts as a cofactor for the anticoagulant protein C activation by protein S.[2] [3]

Activation of factor V to factor Va is done by cleavage and release of the B domain, after which the protein no longer assists in activating protein C. The protein is now divided to a heavy chain, consisting of the A1-A2 domains, and a light chain, consisting of the A3-C1-C2 domains. Both form non-covalently a complex in a calcium-dependent manner. This complex is the pro-coagulant factor Va.[2]

Physiology

Factor V synthesis occurs in the liver, principally. The molecule circulates in plasma as a single-chain molecule with a plasma half-life of 12–36 hours.[4]

Factor V is able to bind to activated platelets and is activated by thrombin. On activation, factor V is spliced in two chains (heavy and light chain with molecular masses of 110000 and 73000, respectively) which are noncovalently bound to each other by calcium. The thereby activated factor V (now called FVa) is a cofactor of the prothrombinase complex: The activated factor X (FXa) enzyme requires calcium and activated factor V to convert prothrombin to thrombin on the cell surface membrane.

Factor Va is degraded by activated protein C, one of the principal physiological inhibitors of coagulation. In the presence of thrombomodulin, thrombin acts to decrease clotting by activating Protein C; therefore, the concentration and action of protein C are important determinants in the negative feedback loop through which thrombin limits its own activation.

Role in disease

Various hereditary disorders of factor V are known. Deficiency is associated with a rare mild form of hemophilia (termed parahemophilia or Owren parahemophilia), the incidence of which is about 1:1,000,000. It inherits in an autosomal recessive fashion.

Other mutations of factor V are associated with venous thrombosis. They are the most common hereditary causes for thrombophilia (a tendency to form blood clots). The most common one of these, factor V Leiden, is due to the replacement of an arginine residue with glutamine at amino acid position 506 (R506Q). All prothrombotic factor V mutations (factor V Leiden, factor V Cambridge, factor V Hong Kong) make it resistant to cleavage by activated protein C ("APC resistance"). It therefore remains active and increases the rate of thrombin generation.

History

Until the discovery of factor V, coagulation was regarded as a product of four factors: calcium (IV) and thrombokinase (III) together acting on prothrombin (II) to produce fibrinogen (I); this model had been outlined by Paul Morawitz in 1905.[5]

The suggestion that an additional factor might exist was made by Dr Paul Owren (1905–1990), a Norwegian physician, during his investigations into the bleeding tendency of a lady called Mary (1914–2002). She had suffered from nosebleeds and menorrhagia (excessive menstrual blood loss) for most her life, and was found to have a prolonged prothrombin time, suggesting either vitamin K deficiency or chronic liver disease leading to prothrombin deficiency. However, neither were the case, and Owren demonstrated this by correcting the abnormality with plasma from which prothrombin had been removed. Using Mary's serum as index, he found that the "missing" factor, which he labeled V (I-IV having been used in Morawitz' model), had particular characteristics. Most investigations were performed during the Second World War, and while Owren published his results in Norway in 1944, he could not publish them internationally until the war was over. They appeared finally in The Lancet in 1947.[5][6]

The possibility of an extra coagulation factor was initially resisted on methodological grounds by Drs Armand Quick and Walter Seegers, both world authorities in coagulation. Confirmatory studies from other groups led to their final approval several years later.[5]

Owren initially felt that factor V (labile factor or proaccelerin) activated another factor, which he named VI. VI was the factor that accelerated the conversion from prothrombin to thrombin. It was later discovered that factor V was "converted" (activated) by thrombin itself, and later still that factor VI was simply the activated form of factor V.[5]

The complete amino acid sequence of the protein was published in 1987.[7] In 1994 factor V Leiden, resistant to inactivation by protein C, was described; this abnormality is the most common genetic cause for thrombosis.[8]

Interactions

Factor V has been shown to interact with Protein S.[9][10]

References

  1. Villoutreix BO, Dahlbäck B (June 1998). "Structural investigation of the A domains of human blood coagulation factor V by molecular modeling". Protein Science. 7 (6): 1317–25. doi:10.1002/pro.5560070607. PMC 2144041. PMID 9655335.
  2. 2.0 2.1 Thorelli E, Kaufman RJ, Dahlbäck B (June 1998). "The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V". The Journal of Biological Chemistry. 273 (26): 16140–5. doi:10.1074/jbc.273.26.16140. PMID 9632668.
  3. Macedo-Ribeiro S, Bode W, Huber R, Quinn-Allen MA, Kim SW, Ortel TL, Bourenkov GP, Bartunik HD, Stubbs MT, Kane WH, Fuentes-Prior P (November 1999). "Crystal structures of the membrane-binding C2 domain of human coagulation factor V". Nature. 402 (6760): 434–9. doi:10.1038/46594. PMID 10586886.
  4. Huang JN, Koerper MA (November 2008). "Factor V deficiency: a concise review". Haemophilia. 14 (6): 1164–9. doi:10.1111/j.1365-2516.2008.01785.x. PMID 19141156.
  5. 5.0 5.1 5.2 5.3 Stormorken H (February 2003). "The discovery of factor V: a tricky clotting factor". Journal of Thrombosis and Haemostasis. 1 (2): 206–13. doi:10.1046/j.1538-7836.2003.00043.x. PMID 12871488.
  6. Owren PA (April 1947). "Parahaemophilia; haemorrhagic diathesis due to absence of a previously unknown clotting factor". Lancet. 1 (6449): 446–8. doi:10.1016/S0140-6736(47)91941-7. PMID 20293060.
  7. Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG (July 1987). "Complete cDNA and derived amino acid sequence of human factor V". Proceedings of the National Academy of Sciences of the United States of America. 84 (14): 4846–50. doi:10.1073/pnas.84.14.4846. PMC 305202. PMID 3110773.
  8. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (May 1994). "Mutation in blood coagulation factor V associated with resistance to activated protein C". Nature. 369 (6475): 64–7. doi:10.1038/369064a0. PMID 8164741.
  9. Heeb MJ, Kojima Y, Rosing J, Tans G, Griffin JH (December 1999). "C-terminal residues 621-635 of protein S are essential for binding to factor Va". The Journal of Biological Chemistry. 274 (51): 36187–92. doi:10.1074/jbc.274.51.36187. PMID 10593904.
  10. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH (February 1993). "Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C". The Journal of Biological Chemistry. 268 (4): 2872–7. PMID 8428962.

Further reading

External links


Linked-in.jpg